Oncopeptides (BATS-CHIXE:ONCOS) - Aktienkurs, Nachrichten und Analyse

ONCOS Aktienübersicht

A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Mehr Details

ONCOS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 87.42%

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen (SEK9M)

Aktien sind hochgradig illiquide

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung (SEK942M)

+ 2 mehr Risiken

Oncopeptides AB (publ) Wettbewerber

Tissue Regenix Group

AIM:TRX

UK£41.0m

e-therapeutics

AIM:ETX

UK£52.6m

Faron Pharmaceuticals Oy

AIM:FARN

UK£177.9m

Bioventix

AIM:BVXP

UK£193.1m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Oncopeptides
Historische Aktienkurse
Aktueller Aktienkurs	SEK 11.13
52-Wochen-Hoch	SEK 42.51
52-Wochen-Tief	SEK 11.01
Beta	-0.61
11 Monat Veränderung	0%
3 Monate Veränderung	-1.59%
1 Jahr Veränderung	n/a
33 Jahre Veränderung	-91.38%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-91.40%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	ONCOS	GB Biotechs	GB Markt
7D	0%	0.8%	0.4%
1Y	n/a	-13.1%	7.9%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie ONCOS im Vergleich zur Branche UK Biotechs abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie ONCOS im Vergleich zum UK Markt abgeschnitten hat.

Preisvolatilität

Is ONCOS's price volatile compared to industry and market?
ONCOS volatility
ONCOS Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stabiler Aktienkurs: ONCOS hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von ONCOS im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2000	59	Monica Shaw	www.oncopeptides.com/sv

Oncopeptides AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Oncopeptides im Vergleich zum Marktanteil des Unternehmens?
ONCOS grundlegende Statistiken
Marktanteil	SEK 942.15m
Gewinn(TTM)	-SEK 310.39m
Umsatz(TTM)	SEK 9.48m

99.4x

Kurs-Umsatz-Verhältnis

-3.0x

Kurs-Gewinn-Verhältnis

Ist ONCOS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ONCOS Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 9.48m
Kosten der Einnahmen	SEK 17.00k
Bruttogewinn	SEK 9.46m
Sonstige Ausgaben	SEK 319.85m
Umsatz	-SEK 310.39m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

Aug 10, 2023

Gewinn per Aktie (EPS)	-3.29
Bruttomarge	99.82%
Nettogewinnspanne	-3,274.49%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich ONCOS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ONCOS Aktienübersicht

Belohnungen

Risikoanalyse

Oncopeptides AB (publ) Wettbewerber

AIM:TRX

UK£41.0m

AIM:ETX

UK£52.6m

AIM:FARN

UK£177.9m

AIM:BVXP

UK£193.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Recent updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Insufficient new directors

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Insufficient new directors

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Insufficient new directors

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Forecast to breakeven in 2024

Insufficient new directors

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Insufficient new directors

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time

Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology

Oncopeptides AB (Publ) Presents Phase 3 Ocean Study Results At the IMW Meeting

Oncopeptides AB (publ) Presents New Data from OCEAN and PORT Study - Abstracts Online

Deputy CEO & CFO recently bought kr82k worth of stock

No longer forecast to breakeven

Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

Forecast to breakeven in 2023

Insider recently bought kr200k worth of stock

Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean Study Evaluating the Efficacy and Safety of Melflufen

Forecast breakeven pushed back to 2024

Oncopeptides AB (Publ) Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Erträge & Einnahmen